|Bid||186.50 x 1000|
|Ask||189.40 x 800|
|Day's range||186.42 - 192.61|
|52-week range||176.36 - 242.99|
|Beta (5Y monthly)||0.60|
|PE ratio (TTM)||22.42|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||251.30|
Vertex Pharmaceuticals (NASDAQ: VRTX) has given more than one investor a headache over the past year. Investors worry that Vertex is struggling to expand beyond its core portfolio of cystic fibrosis (CF) treatments. Considering the time Vertex shares have spent in the doldrums, you may be getting a little impatient.
The FDA grants a Regenerative Medicine Advanced Therapy designation to CRISPR Therapeutics' (CRSP) CTX110 targeting CD19+ B-cell malignancies.
Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) each have their own strengths. Vertex has developed a blockbuster portfolio of cystic fibrosis (CF) treatments. CRISPR is working on gene-editing treatments for a variety of serious diseases.